- Home
- REPL
REPL
Replimune Group Inc.
as 12-20-2024 4:00pm EST
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WOBURN |
| Market Cap: | 897.3M | IPO Year: | 2018 |
| Target Price: | $17.50 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.92 - $17.00 | Next Earning Date: | 02-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 300.41% |
Stock Insider Trading Activity of Replimune Group Inc. (REPL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Sushil | REPL | Chief Executive Officer | Dec 16 '24 | Sell | $12.42 | 10,000 | $124,200.00 | 202,014 | |
| Sarchi Christopher | REPL | Chief Commercial Officer | Nov 18 '24 | Sell | $10.78 | 5,207 | $56,131.46 | 87,045 |
Latest Replimune Group Inc. News
REPL Breaking Stock News: Dive into REPL Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Replimune Prices Upsized $140 Million Offerings
GlobeNewswire
a month ago
Replimune Announces Pricing of Upsized Public Offering
MT Newswires
a month ago
Replimune Plans $125 Million Stock Sale, Net Proceeds to Fund Prospective Skin Cancer Treatment
GlobeNewswire
a month ago
Replimune Announces Proposed Public Offering
Benzinga
a month ago
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
Zacks
a month ago
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
Investing.com
a month ago
Replimune's stock surges 19% after-hours on FDA BLA submission
MT Newswires
a month ago
Replimune Files RP1 Biologics License Application With US FDA; Gets Breakthrough Therapy Designation for RP1
Compare REPL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REPL Replimune Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.